We are live on
!
Find out more
VC
Vivo Capital Portfolio holdings
AUM
$1.2B
1-Year Est. Return
911.44%
This Fund
S&P 500
This Quarter
Est. Return
+35.03%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$893M
AUM Growth
-$316M
(-26%)
Cap. Flow
-$200M
Cap. Flow
% of AUM
-22.43%
Top 10 Holdings %
Top 10 Hldgs %
73.65%
Holding
46
New
3
Increased
4
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$22.1M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$10.9M |
| 3 |
DRUG
Bright Minds Biosciences
DRUG
|
+$8.85M |
| 4 |
Delcath Systems
DCTH
|
+$7.51M |
| 5 |
Trevi Therapeutics
TRVI
|
+$6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Harmony Biosciences
HRMY
|
+$104M |
| 2 |
SVA
Sinovac Biotech, Ltd
SVA
|
+$76.3M |
| 3 |
VRNA
Verona Pharma
VRNA
|
+$47.5M |
| 4 |
Viridian Therapeutics
VRDN
|
+$15.1M |
| 5 |
ALX Oncology
ALXO
|
+$7.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Verastem
VSTM
$511M
| $7.95M | 0.89% |
1,538,461
| – | – |
|
27
Unicycive Therapeutics
UNCY
$142M
| $7.92M | 0.89% |
997,015
+550,000
| +123% | +$3.04M |
|
|
RGLS
28
DELISTED
Regulus Therapeutics
RGLS
| $7.9M | 0.89% |
5,000,000
| – | – |
|
|
SLN
29
Silence Therapeutics
SLN
$528M
| $7.61M | 0.85% |
1,105,454
| – | – |
|
|
CMPS
30
Compass Pathways
CMPS
$1.59B
| $6.08M | 0.68% |
1,608,000
| – | – |
|
|
IOBT
31
DELISTED
IO Biotech
IOBT
| $5.68M | 0.64% |
6,173,439
| – | – |
|
32
Aligos Therapeutics
ALGS
$29.4M
| $5.65M | 0.63% |
141,879
| – | – |
|
33
Compass Therapeutics
CMPX
$357M
| $5.16M | 0.58% |
3,556,023
| – | – |
|
|
ALLK
34
DELISTED
Allakos
ALLK
| $3.58M | 0.4% |
2,956,110
| – | – |
|
35
Corbus Pharmaceuticals
CRBP
$174M
| $1.97M | 0.22% |
166,794
| – | – |
|
36
Bolt Biotherapeutics
BOLT
$7.59M
| $1.88M | 0.21% |
176,065
| – | – |
|
37
Tenax Therapeutics
TENX
$517M
| $1.29M | 0.14% |
208,333
| – | – |
|
|
DBVT
38
DBV Technologies
DBVT
$811M
| $98.9K | 0.01% |
32,020
-238,867
| -88% | -$814K |
|
39
Q32 Bio
QTTB
$480M
| $70.7K | 0.01% |
20,559
| – | – |
|
40
Precision BioSciences
DTIL
$188M
| $17.8K | ﹤0.01% |
4,675
| – | – |
|
|
ADVM
41
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-833,333
| Closed | -$5.85M |
|
|
42
ALX Oncology
ALXO
$265M
| – | – |
-4,034,522
| Closed | -$7.34M |
|
43
Codexis
CDXS
$154M
| – | – |
-388,144
| Closed | -$1.2M |
|
44
enGene Therapeutics
ENGN
$120M
| – | – |
-678,705
| Closed | -$4.48M |
|
|
45
Harmony Biosciences
HRMY
$2.25B
| – | – |
-2,606,247
| Closed | -$104M |
|
|
SVA
46
DELISTED
Sinovac Biotech, Ltd
SVA
| – | – |
-11,800,000
| Closed | -$76.3M |
|
Similar funds
SGDR
FCCPG
AIM
SC
MB
CCM
LWIC
TIM
Vivo Capital's Q4 2024 Portfolio in Review
As of Q4 2024, Vivo Capital held 46 positions worth $893M, down 26% from $1.21B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Vivo Capital withdrew a net $200M in Q4 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Harmony Biosciences, an estimated $104M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Vivo Capital opened a new position in Aclaris Therapeutics worth $22M.
- Vivo Capital's largest Q4 2024 buy was Aclaris Therapeutics: 8,888,888 shares worth $22M.
- Vivo Capital added most to Delcath Systems in Q4 2024, an estimated $7.51M increase.
- Vivo Capital's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $47.5M.
- Vivo Capital fully exited Harmony Biosciences in Q4 2024, selling an estimated $104M.
- Vivo Capital's ten largest holdings make up 74% of its $893M portfolio in Q4 2024.
- Vivo Capital opened 3 new positions and closed 6 in Q4 2024.
- Vivo Capital's portfolio value fell 26% quarter-over-quarter to $893M.
Based on Vivo Capital's 13F filing for Q4 2024, filed 13 Feb 2025.